December 18th 2019
Matthew P. Goetz, MD, discusses the current treatment landscape for patients with estrogen receptor-positive, HER2-negative breast cancer who harbor ESR1 mutations, and provided an overview of the ELAINE trial.
December 16th 2019
Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.
December 6th 2019
Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.
December 4th 2019
David F. Penson, MD, MPH, MMHC, discusses the current armamentarium and ongoing research in prostate cancer.
December 3rd 2019
Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.
November 27th 2019
Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.
Mary J. Fidler, MD, discusses how recent research has impacted the EGFR-mutant non–small cell lung cancer landscape.
Raajit K. Rampal, MD, PhD, discusses current available treatments for patients with polycythemia vera and myelofibrosis, as well as the unmet needs in this area of research.
Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells.
Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.
November 26th 2019
Sham Mailankody, MBBS, discusses ongoing research and recent advances in relapsed/refractory multiple myeloma.
November 21st 2019
Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.
November 19th 2019
David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.
Azadeh Namakydoust, MD, discusses recent advancements in lung cancer and what the future holds.
November 18th 2019
Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.
November 16th 2019
Bradley G. Somer, MD, discusses the emergence of biosimilars in oncology
November 13th 2019
Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.
November 12th 2019
Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.
Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.
November 9th 2019
Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.